Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies
Philipp Haselmayer(Merck KGaA, Darmstadt (Germany)), Hong Ji(Loma Linda University)
Cited by 38
Related Papers
Arthritis Critically Dependent on Innate Immune System Players
|Immunity|2002|694
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
|The Journal of Immunology|2019|145